Randomized Phase II Study of SGI-110 5 Days, Versus 5 Days + Idarubicin in Previously Untreated Patients >/= 70 Years With Acute Myeloid Leukemia
Phase of Trial: Phase II
Latest Information Update: 06 Jun 2017
At a glance
- Drugs Guadecitabine (Primary) ; Cladribine; Idarubicin
- Indications Acute myeloid leukaemia
- Focus Adverse reactions; Therapeutic Use
- 06 Jun 2017 Results (n=34) presented at the 53rd Annual Meeting of the American Society of Clinical Oncology
- 24 Oct 2016 Status changed from active, no longer recruiting to recruiting.
- 17 Oct 2016 Status changed from recruiting to active, no longer recruiting.